The Zhitong Finance App learned that Columbite Biotech (06990) is now up more than 5%. As of press release, it has risen 4.54% to HK$165.7, with a turnover of HK$27.472,300.

According to the news, Collumbotai Biotech announced that at the ASCO (American Society of Clinical Oncology) annual meeting, the company's core product TROP-2 ADC SKB264 (lucan satuzumab) clinical data: 1) SKB264 combined with KL-A167 for phase II clinical trials in patients with advanced undriven gene mutations who have not received treatment; 2) SKB264 monotherapy is used in phase III clinical trials at the end of TNBC.

CITIC Construction Investment pointed out that the company published two clinical data on the core product SKB264 on ASCO. Among them, the combination with A167 showed excellent efficacy in first-line treatment of advanced undriven gene mutation NSCLC, and the safety was good; the single drug used in the final phase III clinical treatment of TNBC also had positive results, and it is expected that this indication will be approved in the second half of the year. Partner MSD is actively deploying SKB264 global clinical trials. Currently, it has deployed 9 phase III clinical trials, covering various types of lung cancer, breast cancer, and endometrial cancer. The company currently has 5 products that have entered the NDA stage. We believe that with the clinical advancement of various subsequent products, the company's R&D capabilities in the ADC field will be further recognized.